ArticleAmerican journal of cancer research2025
Efficacy of continuing pembrolizumab after progression on first-line treatment in stage IV non-small cell lung cancer: a prospective real-world study.
Kexin Ruan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.